Stock Events

Stock Events

Genelink 

$0
4
+$0+0% Wednesday 13:30

Statistics

Day High
0
Day Low
0
52W High
0
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14NovExpected
Q4 2011
Q1 2012
Q3 2012
Q3 2012
Q1 2013
Q2 2013
Q3 2013
-0
-0
-0
-0
Expected EPS
N/A
Actual EPS
-0.002

Financials

-142.88%Profit Margin
Unprofitable
2012
2.14MRevenue
-3.05MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GNLKQ. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap20.57B
Illumina provides sequencing and array-based solutions for genetic analysis, directly competing in the genomics space with Genelink's focus on genetic personalization.
Pacific Biosciences of California
PACB
Mkt Cap510.38M
Pacific Biosciences offers long-read sequencing technologies, competing in the broader market of genetic analysis and personalized genomics.
Thermo Fisher Scientific
TMO
Mkt Cap195.7B
Thermo Fisher Scientific offers a wide range of solutions for genetic analysis and personalized medicine, making it a competitor in the life sciences sector.
Qiagen NV
QGEN
Mkt Cap8.5B
Qiagen is a provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the genomics and personalized health space.
Bionano Genomics
BNGO
Mkt Cap14.31M
Bionano Genomics provides tools for genomic analysis, directly competing in the genetic analysis market that includes personalized genetic services.
Guardant Health
GH
Mkt Cap11.85B
Guardant Health focuses on liquid biopsies and cancer diagnostics, competing in the personalized medicine and genomics field.
Intellia Therapeutics
NTLA
Mkt Cap1.77B
Intellia Therapeutics is involved in CRISPR gene editing, a technology that has broad applications in personalized medicine, making it a competitor in the innovative genetic solutions market.
CRISPR Therapeutics
CRSP
Mkt Cap5.57B
CRISPR Therapeutics is focused on developing gene-based medicines, directly competing in the field of personalized genetic treatments and therapies.

About

GeneLink, Inc. offers 12-gene DNA assessment services. The company also provides health custom supplements. In addition, it formulates a line of skin care products. The company was founded in 1994 and is based in Orlando, Florida.
Show more...
CEO
Dr. Bernard L. Kasten Jr., Ph.D., M.D.
Employees
14
Country
United States
ISIN
US36870F1075

Listings

OTC Link
US
GNLKQ

0 Comments

Share your thoughts

FAQ

What is Genelink stock price today?▼
The current price of GNLKQ is $0 USD — it has increased by +0% in the past 24 hours. Watch Genelink stock price performance more closely on the chart.
What is Genelink stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genelink stocks are traded under the ticker GNLKQ.
What were Genelink earnings last quarter?▼
GNLKQ earnings for the last quarter are -0 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Genelink revenue for the last year?▼
Genelink revenue for the last year amounts to 2.14M USD.
What is Genelink net income for the last year?▼
GNLKQ net income for the last year is -3.05M USD.
How many employees does Genelink have?▼
As of April 24, 2026, the company has 14 employees.
In which sector is Genelink located?▼
Genelink operates in the Health & Wellness sector.
When did Genelink complete a stock split?▼
Genelink has not had any recent stock splits.
Where is Genelink headquartered?▼
Genelink is headquartered in Orlando, United States.